PDL chief resigns in wake of investor wrangle
Another biotech CEO bites the dust after tangling with a key investor. PDL BioPharma's CEO has decided to step aside after a company probe cleared him of charges leveled by the biotech's biggest shareholder. Mark McDade says he will leave by the end of this year, following a bitter fight with Third Point, which claimed the CEO had dropped the ball on a big deal with a major pharma company, missed projections and bungled the company's finances. The company's finance committee, though, concluded that there was no merit to Third Point's claims. Analysts generally applauded the planned exit, which triggered a surge in PDL's shares.
- check out the announcement on McDade's resignation
- here's the report on PDL from Forbes
Related Articles:
Biotech CEOs face rising fury of angry investors. Report
PDL BioPharma rises on shareholder complaint. Report
PDL therapy fails endpoints in Phase III. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
